Unlocking the Potential of Natural Killer and T Cells
Treating Cancer by Activating the Patient's Own Immune System
Our Vision
At AGENTA Therapeutics, our vision is to be the leader in the novel Natural Killer cell and T cell-targeted checkpoint inhibitor market.
Our Expertise
AGENTA is led by a team of established business and scientific leaders with decades of successful track record. AGENTA’s game-changing technology & patents have been researched and invented by the Wistar Institute lab of Professor David B. Weiner, AGENTA’s co-founder.
Our Innovation
AGENTA has the potential to dramatically improve cancer treatment with patent-protected, first-in-class immune checkpoint inhibitors empowering novel NK cell and T cell-based pathways.